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ABSTRACT 30 
We report the results of a symposium aimed at identifying validated biomarkers that can be used 31 
to complement clinical observations for diagnosis and prognosis of joint injury leading to equine 32 
osteoarthritis (OA). Biomarkers might also predict pre-fracture change that could lead to 33 
catastrophic bone failure in equine athletes. The workshop was attended by leading scientists in 34 
the fields of equine and human musculoskeletal biomarkers to enable cross-disciplinary 35 
exchange and improve knowledge in both. Detailed proceedings with strategic planning was 36 
written, added to, edited and referenced to develop this manuscript. The most recent information 37 
from work in equine and human osteoarthritic biomarkers was accumulated, including the use of 38 
personalized healthcare to stratify OA phenotypes, transcriptome analysis of anterior cruciate 39 
ligament (ACL) and meniscal injuries in the human knee. The spectrum of “wet” biomarker 40 
assays that are antibody based that have achieved usefulness in both humans and horses, imaging 41 
biomarkers and the role they can play in equine and human OA was discussed. Prediction of 42 
musculoskeletal injury in the horse remains a challenge, and the potential usefulness of 43 
spectroscopy, metabolomics, proteomics, and development of biobanks to classify biomarkers in 44 
different stages of equine and human OA were reviewed. The participants concluded that new 45 
information and studies in equine musculoskeletal biomarkers have potential translational value 46 
for humans and vice versa. OA is equally important in humans and horses, and the welfare issues 47 
associated with catastrophic musculoskeletal injury in horses add further emphasis to the need 48 
for good validated biomarkers in the horse.  49 
Keywords: Biomarkers, Traumatic arthritis, Osteoarthritis  50 
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INTRODUCTION:  51 
Osteoarthritis (OA) is the most common disease affecting the joints in humans and is an 52 
important cause of pain, disability and economic loss
1-3
. Traumatic joint injury and OA are 53 
equally important in the equine athlete
4
, not only for joint disease but also for bone failure. In 54 
September 2014 the third Dorothy Russell Havemeyer Foundation Symposia on Equine 55 
Musculoskeletal Biomarkers was held (the second Havemeyer Foundation Symposium has been 56 
reported
5
). The aim was to identify validated biomarkers that could be used to complement 57 
clinical observations for diagnosis and prognosis of joint injury leading to OA, to predict pre-58 
fracture subchondral bone disease which can lead to catastrophic bone failure in equine athletes, 59 
and to discuss development of a point of care diagnostic platform.  60 
 61 
The definition of a biomarker varies but a recent consensus suggests it is “a characteristic that is 62 
objectively measured and evaluated as an indicator of normal biologic processes, pathogenic 63 
processes, or pharmacologic responses to a therapeutic intervention”
6
. Further, this definition 64 
stated that “biomarkers can be anatomic, physiologic, biochemical or molecular parameters 65 
associated with the presence and severity of specific diseases and are detectable by a variety of 66 
methods including physical examination, laboratory assays, and imaging”. Biomarkers have been 67 
differentiated into “dry” (e.g. imaging parameters) and “wet” biomarkers (genetic and 68 
biochemical entities that can be detected in blood, serum, urine, synovial fluid (SF) and tissues) 69 
in OA
7
.  70 
 71 
There has been much work in biomarkers in OA in humans for over 25 years
8, 9
.
 
The quest is still 72 
ongoing to define a validated and qualified biomarker panel that could be used to complement 73 
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clinical observations for diagnosis, prognosis and response to treatment, with the most recent 74 
data from the NIH Osteoarthritis Initiative reported
10
. The first report demonstrating a 75 
relationship between biomarkers and osteochondral change in equine joints was published in 76 
1999
11
. Panels of some biomarkers have been validated in experimental equine OA
12,13
, and the 77 
status of equine biomarkers was reviewed in 2005
14
 and more recently in 2015
15
.
 
The Dorothy 78 
Russell Havemeyer Foundation Symposia in 2005, 2009 and recently in 2014 have allowed 79 
exchange of updated information in human and equine musculoskeletal biomarkers as well as 80 
planning best paths for the future in both disciplines. The current narrative review represents the 81 
key findings from the presentations by the attendees, the issues and questions arising from their 82 
discussion and the formal break-out sessions held at the 2014 Symposia.  83 
 84 
Equine musculoskeletal biomarkers: current knowledge and future needs  85 
Previous studies have promoted development of targeted molecular diagnostics and predictive 86 
biomarkers as models for personalized equine orthopedic medicine
5, 14, 15
.
 
Diagnostics are sought 87 
that are non-invasive, repeatable/reproducible and have specificity and sensitivity for early stages 88 
of OA.
16
 Spontaneous joint disease is a common clinical problem in the horse and surveys 89 
estimate that up to 60% of lameness is related to OA
17
. There is therefore a need for diagnostics 90 
designed to predict risk of clinical injury and not just manage the extent of OA, bone disease, 91 
catastrophic fracture, and tendon/ligament injury, but to monitor the health and training of 92 
competition horses and prevent such injuries. This workshop focused on the current status of 93 
diagnostic and point of care platforms for predictive biomarkers.  94 
  95 
Biomarkers in human OA - current state of the art in osteoarthritis biomarkers:  96 
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There is an urgent need for qualified biomarkers to monitor OA development, predict the long-97 
term clinical treatment response and outcome, and identify individuals with the highest risk of 98 
disease progression
7,
 
9, 16, 18
. Osteoarthritis biomarkers could assist clinical trials by delivering 99 
essential early information of treatment response, speeding up compound evaluation, and thereby 100 
making OA a more manageable target for new drug development. Since a disease starts when 101 
detected by the best marker available to define it, herein lies the power of biomarkers. This is 102 
especially important for OA, a disease with a prolonged asymptomatic molecular and pre-103 
radiographic phase. Biomarkers could provide an early warning of biochemical and structural 104 
alterations leading to earlier treatment prior to irreversible disease, which is likely recalcitrant to 105 
therapy. 106 
 107 
An Osteoarthritis Research Society International (OARSI) White Paper
7
 was produced in 108 
response to the Food and Drug Administration (FDA) call for a critical appraisal of fundamentals 109 
of the science related to biomarkers of OA, particularly relating to drug development. A 110 
subsequent OARSI White Paper reviewed FDA guidance on biomarkers and made 111 
recommendations for their use in preclinical development and phase I to IV clinical trials
18
. 112 
These documents catalyzed the OA Biomarker Consortium study managed by the Foundation for 113 
the National Institutes of Health (FNIH)
10
 and highlight how advances in the field of OA 114 
research and treatments can be accelerated by a systematic paradigm that encompasses 115 
development, validation, qualification and regulatory approval of OA-related biomarkers for 116 
clinical trial and clinical use (also see http://oarsi.org).  117 
 118 
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In addition to robust disease definitions, there is a recognized need for a consensus on a 119 
nomenclature defining the disease. According to the FDA
19
 the "currently used disease 120 
classification systems define diseases primarily on the basis of their signs and symptoms”. 121 
Consequently, many disease subtypes with distinct molecular causes are still classified as one 122 
entity, with little ability to stratify or link distinct phenotypes. The National Academy of 123 
Sciences has called for a “New Taxonomy” of disease to advance our understanding of disease 124 
pathogenesis and improve health, that defines and describes diseases on the basis of their 125 
intrinsic biology in additi n to traditional signs and symptoms
20
. Biomarkers are key to this new 126 
taxonomy for heterogenous diseases such as OA. To aid in this, a standardized nomenclature has 127 
been proposed, describing disease (molecular, anatomic and physiological aspects) and illness 128 
aspects of OA
21
.
 
 129 
 130 
Use of personalized health care (PHC) to stratify OA phenotypes  131 
OA is a heterogeneous disorder, with numerous drivers of disease progression. However, up to 132 
50% of OA patients in clinical studies and approximately 85% in the background population do 133 
not show both symptom and structural progression over 2 years
22,23
. It is therefore important to 134 
identify the individuals that progress and determine the drivers of progression. This would enable 135 
enriching of clinical trial populations, and when effective treatment is available to slow disease 136 
progression, to identify those in need of it. There is a need to pair the paramount risk factor for 137 
progression with personalized treatment approaches, in which “one size does not fit all”. A 138 
number of drivers for PHC in OA have been identified
24
:
 
1) Identification of patients who 139 
respond optimally, with the highest efficacy and lowest safety concerns, to a given treatment; 2) 140 
Specific development strategy for a selected subpopulation of patients; and 3) Efficient use of 141 
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healthcare resources.
 
To date, three different OA subpopulations have been identified: 1) 142 
Inflammation mediated OA; 2) Subchondral bone turnover driven OA; and 3) Trauma driven 143 
OA. Biomarkers can identify different pathophysiological processes potentially leading to 144 
identification of these phenotypes (Figure 1 (from Lotz et al 2013
24,25
).  
 
145 
 146 
Transcriptome analyses of meniscus and anterior cruciate ligament injuries may provide 147 
insights into early OA  148 
These were novel discovery studies seeking to determine signaling pathways and specifically 149 
expressed transcripts that are different between samples. As with most transcriptomic profiling 150 
studies, these investigations are usually undertaken as “hypothesis-free” discovery studies, and 151 
do not rely on previous investigations to develop preliminary hypotheses. Clinical studies of 152 
athletes and revision anterior cruciate ligament (ACL) reconstruction patients indicate that 153 
having a partial meniscectomy, increasing age and elevated BMI are all associated with 154 
degenerative changes in knee articular cartilage. Englund and colleagues have suggested that 155 
weakening of the meniscus due to processes similar to OA may be sentinel for the disease
26
. 156 
However, little is known about the molecular signatures in injured meniscus. An extensive 157 
analysis of gene expression from meniscal fragments recovered from meniscal repair surgery 158 
was evaluated for association with the presence or absence of a concomitant ACL injury, age, 159 
BMI and articular cartilage disease in the patient
27-30
. Transcripts associated with extracellular 160 
matrix (ECM) synthesis were down regulated in obese individuals (BMI >30) perhaps indicating 161 
a higher risk of developing meniscus degeneration. Transcripts up-regulated in obese compared 162 
to lean or overweight patients were associated with increased apoptosis and suppression of ECM 163 
deposition. Patients >40 years of age demonstrated repression of genes for skeletal development, 164 
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cartilage development and cartilage ECM synthesis and elevation of genes involved in cell cycle 165 
and cell division, immune response and inflammation pathways. Results such as these may 166 
provide a molecular rationale for the known clinical effects of partial meniscectomy, increasing 167 
age, and increasing obesity on the development of cartilage degeneration
31-33
.  168 
 169 
Further investigation of the relative gene expression levels in the ACL at various times after 170 
injury from acute (<3 months) to chronic (>12 months) showed that processes representing 171 
angiogenesis were repressed in acute tears. In intermediate tears, processes representing stem cell 172 
proliferation concomitant with cellular component organization were elevated. In chronic tears, 173 
processes denoting myosin filament organization were elevated while those representing cellular 174 
component organization and ECM organization were repressed. An ACL tear appears to 175 
stimulate local repair processes early after rupture that recede over time. Further transcriptome 176 
analysis of injured and OA joint tissues may provide candidates for molecular biomarkers as well 177 
as targets for treatment that would reduce the risk of developing OA 
29,32-33
. 178 
 179 
Fluid (“wet”) biomarker assays that are antibody based 180 
Biomarker assessment by immunologic assay has been the standard for analysis in both humans 181 
and horses (reviewed recently)
14, 15
. Progress continues with development of biomarkers for 182 
human OA and their use in clinical trials
7, 16, 18 
and knowledge has advanced in parallel in the 183 
horse (Table S1).
5,15
 Studies in the horse have shown significant exercise related changes in 184 
serum biomarkers of collagen metabolism in young horses
33
. Equine serum markers have also 185 
been shown to distinguish changes associated with exercise from pathologic change in exercising 186 
horses, and to correlate to clinical parameters of pain in an equine OA model
12
. A clinical study 187 
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in 238 racehorses, employing monthly musculoskeletal examinations and blood samples, showed 188 
that it was possible to correctly predict horses that would sustain an injury 74% of the time
34
. 189 
 190 
Recent work evaluating proteinases has shown that: 1) the presence of lumican and a 29kD 191 
lumican catabolite increased with the onset and progression of OA
35,36
; 2) a splice variant of one 192 
of the aggrecanases (ADAMTS4) was identified that appears to be specifically synthesized by 193 
human OA synovium and is associated with aggrecan degradation in the superficial zone of 194 
articular cartilage
37
; and 3) synovial fluid ADAMTS4 activity is a marker of inflammation and 195 
effusion
38
.  Such findings have biologic/disease rationale as confirmed by OA onset in a 196 
STR/ORT mouse model being significantly reduced using monoclonal antibodies directed 197 
against substrate recognition domains of ADAMTS5
39
.  198 
 199 
An anti-cathepsin K antibody has demonstrated significant involvement of cathepsin K in 200 
naturally occurring equine and human OA
40-43
.
 
In equine OA cartilage an alternate equine type II 201 
collagen specific cathepsin K cleavage site was identified in the N-terminal region of the C-202 
terminal collagen fragment using proteomic and immunological techniques
43
. A novel ELISA 203 
assay (C2K77) has been developed to measure the activity of cathepsin K in  culture media 204 
and is being validated in body fluids44. 205 
 206 
While trauma is pivotal in the pathogenesis of human knee OA, seemingly equivalent injuries do 207 
not invariably result in post-traumatic (ptOA). For instance, only 50% of patients with ACL 208 
rupture develop ptOA 10-15 years later, and these numbers are not substantially affected by 209 
surgical reconstruction and “restoration” of joint biomechanics
45-48
. This suggests that factors 210 
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other than joint instability may play a role in the risk, rate of onset, and progression of ptOA after 211 
injury. Differences between non-ptOA inducing (sham) and ptOA-inducing joint injury in mice 212 
showed differing phases of synovial inflammation with distinct cyclically increased macrophage, 213 
CD4 and CD8 T-cell infiltration into the synovium without associated systemic change. Data 214 
from Jaffa mice (protected from cartilage damage) suggest that proteolysis of aggrecan by 215 
ADAMTS plays a critical role in regulating the inflammatory response in the joint, particularly 216 
in macrophage activation and M1/M2 polarization. As has been done in inflammatory 217 
arthropathies, monitoring the pattern of cell influx into the joint after injury may be diagnostic 218 
and enable differentiation between OA-inducing and non-inducing joint trauma
49-51
.  219 
 220 
Examination of proteins from harvested media in an interleukin-1 beta cartilage explant model 221 
analysed by liquid chromatography mass tandem spectrometry (LC-MS/MS) identified cartilage 222 
oligomeric matrix protein (COMP) as a potential OA diagnostic in horses. The unique fragments 223 
of COMP include the amino acid sequences that form a new terminal (neo-epitope) sequence; 224 
polyclonal antibodies that react specifically with this new cleavage site have now been 225 
developed
52
. It was concluded that an increase in the COMP neo-epitope in synovial fluid from 226 
horses with acute lameness suggested that this has the potential to be a unique candidate 227 
biomarker for the early molecular changes in articular cartilage associated with OA.  228 
 229 
Imaging biomarkers in the horse  230 
Imaging lacks evidence as a biomarker technique for predicting and characterizing 231 
musculoskeletal injuries, especially to inform prognosis. Hurdles include limited ability to 232 
discern normal tissue adaptation from early disease, limited use of frontline volumetric imaging 233 
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techniques (usually due to cost), lack of prospective data on imaging biomarkers in relation to 234 
disease presence and outcome in the horse, modest correlation between pain and imaging results, 235 
and limited follow-up/longitudinal imaging
13,53
.
 
However, progress is being made and novel 236 
techniques including digital radiography, ultrasound, nuclear scintigraphy, computed 237 
tomography (CT) and MRI are developing. The use of digital radiography, nuclear scintigraphy, 238 
CT and MRI to distinguish changes with exercise vs. OA has been published
13
.  239 
 240 
Digital radiography techn logy allows image manipulation to improve lesion detection but a 30-241 
40% change in bone mineral density is still needed to detect lesions, allowing for significant 242 
tissue changes to occur prior to detection
54
. Radiological changes in OA are slow to develop, and 243 
thereby inhibit intervention in a timely fashion. Joint space width has been used for decades as a 244 
measure of joint disease severity, yet it lacks predictive ability for clinical outcomes in humans
55
. 245 
Joint space width measurements in equine femorotibial joints have recently been assessed for 246 
accuracy and standardization of positioning, as in humans, is essential for maximum accuracy
56
.  247 
Radiography, however, continues to be a useful outcome measure in a common model of OA
13
.  248 
 249 
Nuclear scintigraphy has been useful in defining the presence of disease compared to increased 250 
uptake that occurs with exercise alone in horses
57
.
 
Although nuclear scintigraphy appears helpful 251 
in early diagnosis of disease, it lacks the specificity to fully define the lesion, but may be useful 252 
for screening and monitoring OA onset or progression in both horses and humans.  253 
 254 
Computed tomography has been used clinically to detect occult lesions in subchondral bone. 255 
Detection of altered patterns of subchondral bone density by computed tomographic 256 
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osteoabsorptiometry (CTO) has been used to define joint disease in horses
13
. It appears that CTO 257 
density patterns can characterize insidious disease processes, such as palmar osteochondral 258 
disease. Intra-articular application of contrast has also been used and provides critical 259 
information concerning soft tissues of joints
58
, especially those such as the equine femorotibial 260 
joint that can rarely be imaged using MRI
59
. Dual energy CT has also been studied and appears 261 
to have value in characterization of soft tissues and detection of bone marrow edema
60
.  262 
 263 
MRI has revolutionized the detection of subtle joint disease in all species, and in particular, the 264 
detection of soft tissue and articular lesions. However, its resolution is limited and subtle bone 265 
and joint lesions can sometimes be missed
61
. MRI has significant potential as a predictive marker 266 
of disease as shown by many studies including the MRI component of the OARSI/FNIH study
61
. 267 
A recent review has shown that measures of quantitative cartilage morphology, cartilage defect 268 
and bone marrow lesions, bone shape and attrition and subchondral bone area were the most 269 
promising as imaging biomarkers
62
.  270 
 271 
Quantitative MR imaging has improved characterization of articular cartilage matrix (GAG, 272 
collagen and water) in humans and research animals, with limited use in the horse. dGEMRIC 273 
imaging uses intraarticular or IV administration of gadolinium based contrast medium measured 274 
in relation to the fixed-charged matrix components, giving an indication of GAG concentration 275 
in the cartilage matrix
63
. T1rho has been used in people but not horses, and can give information 276 
on GAG content, but can also be influenced by collagen content
64
. Therefore T2 mapping is 277 
often necessary for comparison. Sodium MR imaging is also correlated to GAG, but requires 278 
special equipment and high field strength for scanning
65
. T2 and T2* imaging can be used to 279 
Page 13 of 34
John Wiley & Sons, Inc.
Journal of Orthopaedic Research
For Peer Review
 
 14
characterize collagen content within articular cartilage, but often require long scan times
66
. 280 
Diffusion weighted techniques measure water diffusion through the matrix and appear to have 281 
promise in best characterizing matrix integrity
67
.
  
282 
 
283 
Standing low-field MRI systems have been useful in the horse for identifying osseous pathology, 284 
which appears to carry various (but ill-defined) risks of sustaining catastrophic injury
68,69
, but 285 
their usefulness is limited to the distal limb; because of low quality resolution only rudimentary 286 
visualization of the articular cartilage is possible limiting early identification of cartilage 287 
pathology.  288 
 289 
All imaging modalities to date focus on identifying tissue changes after the initiating insult. 290 
Much like genetic markers, using biomechanical modeling to identify those horses with joints 291 
that may be geometrically predisposed to disease has potential uses for identifying risk and 292 
modulating exercise to lower risk and/or severity of disease
70
. 293 
  294 
The use of spectroscopy as a biomarker: 295 
In the case of naturally occurring equine traumatic OA, the Fourier transform infrared 296 
spectroscopy (FTIR) approach has been confirmed as highly accurate for synovial fluid when 297 
compared to arthroscopy
71
.
 
The limitations of such studies are that they have been conducted on 298 
clinically apparent cases and have not been tested in a preclinical population of horses for which 299 
prospective synovial fluid analysis would be impractical
35
.  300 
 301 
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One of the significant advantages of FTIR as a biomarker tool is that the spectra generated from 302 
serum or any other body fluid, encompass not only known markers but also unknown markers
71
. 303 
Current work has used transmission FTIR that is expensive but more cost effective clinical 304 
platforms are being developed
72
.  305 
 306 
Metabolomics and proteomics: 307 
There has been increasing interest in profiling the metabolome, consisting of the low molecular 308 
weight end products of cell metabolic processes which indicate the cellular function of a given 309 
cell type or tissue under specific conditions
73,74
. The principal analytical techniques used in 310 
metabolomics are mass spectrometry (MS) and nuclear magnetic resonance (NMR) 311 
spectroscopy
75
. Compared to MS, NMR spectroscopy is non-destructive and requires little 312 
sample preparation, and can generate a comprehensive metabolomics profile from intact 313 
biofluids and tissues
76
.
 
However, in certain instances this technique is insufficient to provide 314 
information that will fully characterize a metabolite and MS analysis has the advantage of higher 315 
sensitivity. 316 
 317 
In OA, metabolomic fingerprinting has been performed on urine samples from Hartley guinea-318 
pigs, which spontaneously develop OA
77,78
.
 
MS-based proteomics techniques have also been 319 
used to determine the underlying mechanisms of musculoskeletal aging, OA and tendon injury in 320 
equine SF from normal and OA racing Thoroughbreds as well as equine cartilage and tendon 321 
from normal or diseased young and old donors (Table S1).  322 
 323 
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Proteomic analysis of the OA cartilage secretome identifies molecules with roles in the 324 
pathologic processes and allows the global study of secreted proteins while also potentially 325 
enabling biomarker discovery. In one study an equine degradome using a mass spectrometry-326 
based absolute quantification method using a concatamer of selected quantotypic peptides 327 
representative of proteins (QconCAT) was designed to measure specific cleaved ECM proteins
79
. 328 
There was a significant decrease with age of the mean concentration of aggrecan G3 that is 329 
explained by loss of G3 soon after cartilage aggrecan synthesis and a steady decline in turnover 330 
producing a loss of G3 in the resident aggrecan molecules. The result is that the average size of 331 
aggrecan decreases with age, and a large proportion of aggrecan lacks a G3 domain
80
.  332 
 333 
Matrix assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) was used 334 
to examine proteins in situ at high spatial resolution in an examination of full-thickness equine 335 
cartilage slices; identified ECM proteins included COMP, fibromodulin, biglycan, and type II 336 
collagen. In addition, a number of OA and age specific markers were identified
81
.  337 
 338 
Proteomic profiling of equine synovial fluid from normal and OA metacarpophalangeal joints 339 
using label-free quantification approaches following protein equalization techniques identified 340 
754 proteins in synovial fluid, 593 with a significant Mascot score. Proteins identified included 341 
those relating to matrix proteins, inflammatory factors, complement activation proteins and 342 
proteases. A subset of 10 proteins were identified which were differentially expressed in OA 343 
synovial fluid. This distinct set of proteins could provide potential biomarkers to stratify OA
82
. 344 
Although frequently used in clinical research , substantial challenges remain before this 345 
technology can be employed as a biomarker in a clinical setting 346 
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 347 
Next Generation Sequencing (NGS) and a computational strategy to support biomarker 348 
and therapeutic discovery  349 
With NGS approaches it is possible to identify subtle unique genomic variations encoded in each 350 
individual's genome and identify the transcriptionally active genes in individual tissues. This 351 
provides the ability to explore associated differences in coding or transcriptional activity with 352 
clinical observations, ultimately affording cause-effect relationships that impact aspects of the 353 
individual's health status. Knowledge of the extent of an individual’s unique genomic variation, 354 
which genes are transcriptionally active and the pathway assignments of each gene provides 355 
information about the metabolically active processes and how the host’s tissues metabolic 356 
activity differs after injury compared to a healthy state. Further, this global approach holds the 357 
promise to not only discern early pre-symptomatic disease, but also identify susceptible 358 
individuals. 359 
 360 
In addition to global post-genomic experimental techniques, powerful analytical strategies are 361 
required to fully utilize the resulting large and complex datas ts. To address this need, iterative 362 
feature removal (IFR) analysis was developed to identify molecular features that can be used as 363 
classifiers for metabolic activity and as diagnostics
83
.
 
The IFR process works by repeatedly 364 
building a predictive model on training data using a classifier that assigns non-zero weights to 365 
only a minimal subset of non-redundant features. IFR assists investigators with process 366 
discovery in a way that alternative feature selection approaches cannot. IFR analysis, when 367 
applied to global biological datasets, allows for more comprehensive evaluation of linked 368 
metabolic processes. When applied to transcriptional data, IFR identified sets of genes that were 369 
Page 17 of 34
John Wiley & Sons, Inc.
Journal of Orthopaedic Research
For Peer Review
 
 18
highly predictive even when the sets were comprised of genes that, taken individually, appeared 370 
non-discriminatory. The efforts here not only identify biomarkers that are classifiers for disease, 371 
but also provide biomarkers that hold the potential to screen for disease susceptibility.  372 
 373 
Due to the global analysis offered by NGS, this strategy can also be used to identify pathways 374 
associated with therapeutic intervention and healing.  Based on observations that IGF-I could 375 
function as an anabolic factor for the treatment of OA, a gene therapy approach was taken to 376 
produce IGF-I and NGS was used to map the biological response associated with the observed 377 
healing effects in an equine study
84
. Analysis of the resulting transcriptional response to IGF-I 378 
therapy revealed that genes and metabolic pathways associated with specific extracellular matrix 379 
collagen types were differentially regulated, as in cartilage development and chondrocyte 380 
differentiation. NGS analysis afforded a differential expression fingerprint that could potentially 381 
be used to monitor treatments of OA. 382 
 383 
Biobanks to classify biomarkers in different stages of equine OA:  384 
In order to validate existing and develop new wet biomarkers it is critical that sufficient well-385 
documented equine samples are available to the research community.  Potential biomarkers can 386 
be tested using standard samples from biobanks and classified according to: Burden of disease 387 
(B), Investigative (I), Prognosis (P), and Efficacy of treatment (E), Diagnostic (D) and Safety (S) 388 
(BIPEDS)
85
.
 
Safety was added in a second OARSI White Paper
18
. Four equine biobanks are 389 
actively archiving specimens or are proposed:  390 
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1. Young horses sampled every third month during a training program with speed training 391 
gradually increasing during the study period. This biobank can test potential biomarkers 392 
for D (acute lameness) and P (initiation and progression). 393 
2. Joints, sampled at one abattoir or necropsy. The articular cartilage should be 394 
characterized as being macroscopically? normal or with mild, moderate, or severe 395 
lesions. Radiographic examination of the dissected bones should be included categorising 396 
the bone according to the extent of sclerosis. These structural OA joints can be used for 397 
testing biomarkers as B (degree of structural OA) and D (Structural OA). 398 
3. Horses in conventional training/racing and undergoing arthroscopy of different joints. 399 
The SF is aspirated during arthroscopy, and material from synovial membrane, synovial 400 
capsule and osteochondral fragment, when appropriate, is immersed in buffered formalin.  401 
4. Clinically lame horses examined by routine lameness examination sometimes including 402 
the lameness locator test
86
,
 
evaluating acute and chronic lameness before and after local 403 
anaesthesia. These fluids can test biomarkers for clinical OA as P (prognosis), E 404 
(efficacy) and D (diagnosis). 405 
These biobanks will consist of serum and synovial fluid (SF), and where possible tissues from 406 
synovial membrane/capsule and articular cartilage (including subchondral bone). Samples of the 407 
SF would be analysed for total protein (g/L) and total number of leucocytes, and the remainder 408 
centrifuged for 20 min, 16,000g and aliquots’ (100µ/L) frozen at -80°C and stored until analysed. 409 
Signed ethical approvals and consent of the owners is mandatory for all samples. 410 
 411 
CONCLUSIONS: 412 
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New information and studies in equine musculoskeletal biomarkers have potential translational 413 
value for humans and vice versa. Osteoarthritis is equally important in both humans and horses 414 
and the welfare issues associated with catastrophic musculoskeletal injury in horses add further 415 
emphasis to the need for good validated biomarkers in the horse. Further progress in identifying 416 
useful human and equine biomarkers requires exploratory studies to identify promising 417 
candidates combined with the development of reliable assays. To prove clinical utility and 418 
acquire regulatory approval for a biomarker is a demanding task, requiring retrospective 419 
hypothesis-generating and prospective hypothesis-testing studies in several study populations. 420 
The equine athlete offers a unique “at risk” population with a high incidence of naturally 421 
occurring clinically important musculoskeletal disease including OA, that is ideal for the 422 
discovery and validation of biomarkers across the BIPEDS spectrum. In addition, by having 423 
established inducible models in the same species, the biomarkers can be used in development of 424 
new therapeutics which simultaneously validates their utility in monitoring disease progression 425 
and response to treatment. To take advantage of this opportunity will require establishing 426 
standardised methods of sample collection, reproducible biomarker measurement, and well-427 
documented biobanks akin to those in human medicine. Me ting these challenges will not be 428 
insubstantial, but the potential rewards for the equine industry and how this will inform human 429 
health, are enormous.  430 
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Figure Legend: 671 
Figure 1: Overview of currently used markers in the rheumatology, divided into areas 672 
Inflammation, signalling, matrix destruction, matrix production and differentiation, proteases and 673 
synovial inflammation. Reproduced from Lotz M, Martel-Pelletier J, Christiansen C, et al. Value 674 
of biomarkers in osteoarthritis: current status and perspectives. Ann Rheum Dis 2013;72:1756-675 
63. 676 
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